Goldman Sachs (synagog of Satan) thanks you.


here is what they said a few years ago


Back in 2018 Goldman Sachs published a report titled The Genome Revolution.
It outlined the dangers to sustained profits that true cures, via real medical breakthroughs, would present to investors.
One chapter of that report is titled "Sustainability and pricing... ", and covers the danger to revenue growth in true curative therapies.
It states:
"In the face of exhaustion of prevalent and incident patient pools, companies require further innovation to sustain revenue growth. Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise."
But their version of "innovation" is not true curative therapy, but profit sustainability.